[Therapeutic strategies. Evolution and current status of the European Guidelines on Cardiovascular disease...

Area of Science:

• Cardiology
• Preventive Medicine
• Clinical Guidelines

Context:

• The 2011 European Guidelines on Dyslipidaemias and 2012 Cardiovascular Prevention guidelines introduce updated risk assessment strategies.
• Key changes include defining distinct patient risk categories: 'very high risk' and 'high risk'.

Purpose:

• To outline the updated European guidelines for managing dyslipidaemias and cardiovascular disease prevention.
• To define patient risk stratification and establish specific therapeutic objectives for lipid management.

Summary:

• Identifies 'very high risk' patients (e.g., atherosclerotic disease, diabetes with risk factors, advanced renal failure, SCORE >10%) and 'high risk' patients (e.g., diabetes without risk factors, moderate renal failure, SCORE 5-10%).
• HDL cholesterol and triglycerides are risk modulators, not primary targets. Therapeutic goals are LDL cholesterol <70 mg/dl (or ≥50% reduction) for very high risk, and LDL <100 mg/dl for high risk.
• Lifestyle changes and statin therapy are central to lipid-lowering treatment; other agents are considered if statins are insufficient.

Impact:

• Provides clinicians with updated criteria for identifying and managing patients at risk of cardiovascular events.
• Establishes clear, evidence-based LDL cholesterol targets to guide therapeutic interventions.
• Emphasizes the primary role of statins in achieving lipid-lowering goals, with a framework for alternative treatments.